Now showing items 1-1 of 1

    • Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. 

      Thwaites, G. E.; Scarborough, M.; Szubert, A.; Nsutebu, E.; Tilley, R.; Greig, J.; Wyllie, S. A.; Wilson, P.; Auckland, Cressida; Cairns, J.; Ward, D.; Lal, P.; Guleri, A.; Jenkins, N.; Sutton, J.; Wiselka, M.; Armando, G-R; Graham, C.; Chadwick, P. R.; Barlow, G.; Gordon, N. C.; Young, B.; Meisner, S.; McWhinney, P.; Price, D. A.; Harvey, D.; Nayar, D.; Jeyaratnam, D.; Planche, T.; Minton, J.; Hudson, F.; Hopkins, S.; Williams, J.; Török, M. E.; Llewelyn, M. J.; Edgeworth, J. D.; Walker, A. S. (Elsevier, 2017-12-14)
      Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed ...